1. Scrip

Sosei Backs RNA Activation Through Sizeable Equity And Option Deal

 
• By Sukaina Virji

MiNA hopes the equity investment and acquisition option agreement secured from Sosei results in a 'Heptares-style' arrangement with the Japanese firm.

RNA technology has failed to live up to its early drug discovery potential, but Sosei believes MiNA Therapeutics' 'activating' RNA approach could change all that.

Sosei has agreed to make a strategic investment of £35m into MiNA Therapeutics in return for a 25

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.